KR7002780005 - ICVX (XNAS)

Icosavax, Inc. Acción

Resumen Cifras financieras

Sin cotización

Performance

Day	Week	Month	3 Months	6 Months	1 Year	5 Years
-	-	-	-	0,00 %	-1,86 %	-56,22 %

Company Profile for Icosavax, Inc. Share

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.

Company Data for Icosavax, Inc. Share

Name Icosavax, Inc.

Company Icosavax, Inc.

Symbol ICVX

Website https://icosavax.com

Primary Exchange

NASDAQ

ISIN KR7002780005

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Mr. Adam K. Simpson

Market Capitalization 769 Mio

Country United States of America

Currency USD

Employees 0,1 T

Address 1616 Eastlake Avenue East, 98102 Seattle

IPO Date 2021-07-29

Ticker Symbols

Name	Symbol
NASDAQ	ICVX

More Shares

Investors who Icosavax, Inc. hold also have the following shares in their portfolio:

TOYOTA 19/29 Bond

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Jobs Community Feedback Changelog

Im App Store herunterladen

Bei Google Play herunterladen

All rights reserved © LCP GmbH 2024